Skip to main content

Ovarian Cancer Clinical Trials

Review the ovarian cancer clinical trials on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 151-175 of 296

A Clinical Trial to Test if the Investigational Drug BNT329 is Safe and Potentially Beneficial for People With Advanced Solid Tumors Known to Express the Tumor Marker CA19-9
Status: Active
Location: Memorial Sloan Kettering Cancer Center, New York, New York
Single Protein Encapsulated Doxorubicin for the Treatment of Advanced, Refractory or Relapsed Solid Tumor Malignancies
Status: Active
Location: UC Irvine Health/Chao Family Comprehensive Cancer Center, Orange, California
A Study to Investigate CYC140, in Subjects With Advanced Solid Tumors and Lymphoma
Status: Active
Location: University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania
Tivozanib and Atezolizumab for the Treatment of Advanced, Unresectable, or Metastatic Immunologically Cold Tumor Types
Status: Active
Location: UF Health Cancer Institute - Gainesville, Gainesville, Florida
Lurbinectedin in Combination with Paclitaxel and Bevacizumab for the Treatment of Patients with Platinum-Resistant or Platinum-Refractory Ovarian Cancers
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
CPI-0209 in Combination with Carboplatin for the Treatment of Patients with Platinum Sensitive Recurrent Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Status: Active
Location: University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania
Hyperthermic Intraperitoneal Chemotherapy with Cisplatin After Surgery or Cisplatin Before Surgery for the Treatment of Stage III or IV Ovarian, Fallopian Tube or Peritoneal Cancer
Status: Active
Location: Ohio State University Comprehensive Cancer Center, Columbus, Ohio
Safety and Immunogenicity of Innocell Autologous Cellular Immunotherapy for Recurrent Epithelial Ovarian Cancer
Status: Active
Location: City of Hope Comprehensive Cancer Center, Duarte, California
Fecal Microbiota Transplantation in Treating Immune-Checkpoint Inhibitor Induced-Diarrhea or Colitis in Cancer Patients
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Cirtuvivint and Olaparib for the Treatment of Patients with BRCA/HRD Platinum Resistant Ovarian Cancer
Status: Active
Location: UCHealth University of Colorado Hospital, Aurora, Colorado
MUC1-Activated T Cells for the Treatment of Relapsed and Resistant Ovarian Cancer
Status: Active
Location: Mayo Clinic in Arizona, Scottsdale, Arizona
Talazoparib and Palbociclib, Axitinib, or Crizotinib for the Treatment of Advanced or Metastatic Solid Tumors, TalaCom Trial
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Autologous B7-H3 Chimeric Antigen Receptor T Cells for the Treatment of Recurrent Platinum-Resistant Ovarian Cancer
Status: Active
Location: Stanford Cancer Institute Palo Alto, Palo Alto, California
First-in-Human Study of ATX-295, an Oral Inhibitor of KIF18A, in Patients With Advanced or Metastatic Solid Tumors, Including Ovarian Cancer
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Chimeric Antigen Receptor (CAR) T-cell Therapy with iC9-CAR.B7-H3 T cells for the Treatment of Patients with Recurrent Platinum Resistant or Refractory Epithelial Ovarian Cancer
Status: Active
Location: UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina
Genetically Engineered Cells (FSHCER T cells) for the Treatment of Recurrent Platinum-resistant or Platinum-refractory Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Status: Active
Location: Moffitt Cancer Center, Tampa, Florida
Tumor Treating Fields Therapy in Combination with Chemotherapy for the Treatment of Advanced Solid Tumors Involving the Abdomen or Thorax
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
IACS-6274 with or without Bevacizumab and Paclitaxel or Capivasertib for the Treatment of Advanced Solid Tumors
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Trial of THEO-260 (Administered Via Intraperitoneal Route) in Ovarian Cancer Patients
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
FIH Study to Evaluate Safety, Tolerability, PK, PD & Preliminary Efficacy of AT03-65 With Advanced Solid Tumors
Status: Active
Location: OHSU Knight Cancer Institute, Portland, Oregon
A Study of NPX887 for Participants With Solid Tumors Known to Express B7-H7/HHLA2
Status: Active
Location: Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland
Study of CRX100 as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Malignancies
Status: Active
Location: Stanford Cancer Institute Palo Alto, Palo Alto, California
Clinical Trial of PM54 in Advanced Solid Tumors Patients.
Status: Active
Location: Siteman Cancer Center at Washington University, Saint Louis, Missouri
A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas
Status: Active
Location: University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma
A Study of MGC026 in Participants With Advanced Solid Tumors
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas